Stocky turns companies like KRYS into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Hold. Krystal's 70.8 Growth Compounder Score reflects promising biotech pipeline momentum, but a 45.3 Leadership Alignment Score and 75 Vulnerability Index create meaningful headwinds. FDA regulatory approval dependency and reliance on patent exclusivity designations (Orphan Drug, Fast Track status) are structural risks that could materially compress competitive positioning and valuation if timelines slip or exclusivity windows narrow.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for KRYS:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 62/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates KRYS (KRYS) at 62/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. Krystal's 70.8 Growth Compounder Score reflects promising biotech pipeline momentum, but a 45.3 Leadership Alignment Score and 75 Vulnerability Index create meaningful headwinds. FDA regulatory approval dependency and reliance on
KRYS's current Stocky Verdict is 62/100, placing it in the "Hold" band. This composite combines a 71/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for KRYS yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
KRYS scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
KRYS's Vulnerability Profile scores 75/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to KRYS.
Sign up free and unlock the full analysis on KRYS — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for KRYS in the app.
